Helsinn Healthcare SA
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Helsinn Healthcare SA
The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.
After PEs, Torrent Pharma is speculated to be in the fray for a stake in Cipla. Experts weigh in on the contours of the product and cultural alignment of the two firms, should things move forward and also whether other Indian players could take a shot at the 'once in a lifetime opportunity'.
The UK firm has got the green light in the US to conduct two Phase IIb/III trials of its cancer cachexia candidate S-pindolol but a lot more money needs to be raised to complete them.
Dr Reddy's Laboratories' co-chairman and MD, GV Prasad, talks about his conversations with late founder Dr Anji Reddy, the company’s ‘Horizon 2’ strategy, pricing expectations for CAR-T cell therapies, the promise of the China market, how Indian owner-managed pharma firms are figuring out ways to deal with succession aspects and his new book.
- Medical Devices
- Specialty Pharmaceuticals
- Topical Delivery
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Sapphire Therapeutics
- Helsinn Pharmaceuticals Beijing Co. Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.